Effective July 1, 2025, the following faculty members have been promoted in recognition of their outstanding dedication, innovative research, and significant contributions to the field of hematology.
Stephen Oh, MD, PhD, has been promoted to Professor of Medicine.
Dr. Oh is internationally recognized for his pioneering research on myeloproliferative neoplasms (MPNs)—a group of chronic hematologic malignancies characterized by dysregulated JAK-STAT signaling and risk of progression to secondary acute myeloid leukemia (sAML). His work has significantly advanced our understanding of the molecular and inflammatory pathways driving disease progression in MPNs. Dr. Oh’s translational research aims to identify therapeutic targets and develop improved treatments for patients living with these challenging disorders.
In addition to his research accomplishments, Dr. Oh has demonstrated exceptional leadership as Co-Chief of the Division of Hematology, Program Director of the NHLBI-supported Molecular Hematology T32 training grant, and Co-Head of the Immunomonitoring Laboratory at the Bursky Center for Human Immunology and Immunotherapy. He has received numerous prestigious awards, including the Doris Duke–Damon Runyon Clinical Investigator Award and the American Society of Hematology Scholar Award. He is also an elected member of the American Society for Clinical Investigation. Dr. Oh also serves on multiple national panels and editorial boards, reflecting his influence in the field.
Please join us in congratulating Dr. Oh on this well-deserved recognition of his outstanding contributions to hematology and academic medicine.
Andrew Young, MD, PhD has been promoted to Assistant Professor of Medicine
Dr. Young is a physician-scientist whose research focuses on the genomics of clonal hematopoiesis and the molecular mechanisms driving malignant transformation in hematologic diseases. His work has significantly advanced our understanding of how somatic mutations accumulate in the hematopoietic compartment throughout life and contribute to leukemogenesis.
Dr. Young is investigating how clonal mutations evolve and create disease-specific vulnerabilities in conditions such as myeloproliferative neoplasms (MPNs) and myelodysplastic syndromes (MDS). His recent research includes the development of novel tools for detecting oncogenic fusions and studies into how environmental exposures, such as firefighting or smoking, contribute to clonal evolution and cancer risk.
Please join us in congratulating Dr. Young on this well-earned promotion and in celebrating his impactful contributions to the future of hematologic research and care.